Last Updated: November 16, 2026

Expiring Drug Patents Cheat Sheet
We analyse the patents covering drugs in 134 countries and quickly give you the likely loss-of-exclusivity/generic entry date

➤ Get the Full List

Jordan: These 7 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027

The content of this page is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

Preferred citation:
Friedman, Yali, "Jordan: These 7 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027" DrugPatentWatch.com thinkBiotech, 2026 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
When can SIRTURO (bedaquiline fumarate) generic drug versions launch in Jordan?

Generic name: bedaquiline fumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 05, 2026
Generic Entry Controlled by: Jordan Patent 2,973

SIRTURO is a drug marketed by Janssen Therap. There are two patents protecting this drug.

See drug price trends for SIRTURO.

The generic ingredient in SIRTURO is bedaquiline fumarate. Additional details are available on the bedaquiline fumarate profile page.

When can OSENI (alogliptin benzoate; pioglitazone hydrochloride) generic drug versions launch in Jordan?

Generic name: alogliptin benzoate; pioglitazone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 01, 2027
Generic Entry Controlled by: Jordan Patent 2,650

Drug Price Trends for OSENI
OSENI is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug. There has been litigation on patents covering OSENI

See drug price trends for OSENI.

The generic ingredient in OSENI is alogliptin benzoate; pioglitazone hydrochloride. Additional details are available on the alogliptin benzoate; pioglitazone hydrochloride profile page.

When can KYBELLA (deoxycholic acid) generic drug versions launch in Jordan?

Generic name: deoxycholic acid
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 19, 2027
Generic Entry Controlled by: Jordan Patent 3,172
Patent Title: تركيبة وطريقة وتحضير الصفراء الصناعية (SYNTHETIC BILE ACID COMPOSITION,METHOD,AND PREPARATION)

KYBELLA is a drug marketed by Abbvie. There are fourteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering KYBELLA

The generic ingredient in KYBELLA is deoxycholic acid. Additional details are available on the deoxycholic acid profile page.

When can KYBELLA (deoxycholic acid) generic drug versions launch in Jordan?

Generic name: deoxycholic acid
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 19, 2027
Generic Entry Controlled by: Jordan Patent P20180077
Patent Title: تركيبات وطرق لحمض صفراوي تخليقي (SYNTHETIC BILE ACID COMPOSITIONS AND METHODS)

KYBELLA is a drug marketed by Abbvie. There are fourteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering KYBELLA

The generic ingredient in KYBELLA is deoxycholic acid. Additional details are available on the deoxycholic acid profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in Jordan?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 01, 2027
Generic Entry Controlled by: Jordan Patent 3,643

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can ALIQOPA (copanlisib dihydrochloride) generic drug versions launch in Jordan?

Generic name: copanlisib dihydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 04, 2027
Generic Entry Controlled by: Jordan Patent 3,147
Patent Title: مشتقات 2،3 - داي هيدرو إميدازو}1،2-{c كينازولين بها استبدال مفيدة لعلاج اضطرابات فرط التكاثر الخلوي والامراض المتعلق بتولد الاوعية (Substituted 2,3-dihydroimidazo[ 1,2- c] quinazoline Derivatives Useful for Treating Hyper-Proliferative Disorders And Diseases Associated with Angiogenesis)

ALIQOPA is a drug marketed by Bayer Healthcare. There are three patents protecting this drug.

See drug price trends for ALIQOPA.

The generic ingredient in ALIQOPA is copanlisib dihydrochloride. Additional details are available on the copanlisib dihydrochloride profile page.

When can ZYKADIA (ceritinib) generic drug versions launch in Jordan?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 06, 2027
Generic Entry Controlled by: Jordan Patent 2,980

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.

Jordan Branded and Generic Drug Market: Regulatory Opportunities, Patent Risk, and Commercial Outlook

Last updated: October 11, 2026

Jordan is a regional pharmaceutical manufacturing and registration hub with a strong domestic generic sector, established export infrastructure, and a price-sensitive public procurement system. Branded innovators retain opportunities in specialty medicines, biologics, oncology, rare diseases, and hospital products, but face reimbursement limits, local manufacturing competition, and rapid generic substitution after exclusivity ends.

The main commercial opportunity is regional: companies can use Jordanian registration, manufacturing, and distribution capabilities to reach markets in the Middle East, North Africa, and selected export jurisdictions. The main regulatory challenges are JFDA registration timing, pricing controls, bioequivalence requirements, tender concentration, patent and data-exclusivity analysis, and changing reliance on reference authorities.

How large is Jordan's branded and generic drug market?

Jordan has a relatively small domestic population but a developed pharmaceutical industry. Local manufacturers supply a significant share of domestic pharmaceutical demand and export products to regional and international markets. Industry sources commonly report that Jordanian manufacturers export to more than 70 countries, with products reaching markets in the Middle East, North Africa, Asia, Europe, and the United States (Jordan Association of Pharmaceutical Manufacturers, n.d.).

Market characteristic Assessment
Domestic market Small to medium by regional standards
Local manufacturing Strong, with multiple Jordanian generic manufacturers
Generic penetration High in volume and institutional procurement
Branded medicines Concentrated in patented, specialty, hospital, and originator products
Public procurement Price-sensitive and tender-driven
Private retail market Important for chronic medicines and branded generics
Export role Major strategic driver for Jordanian manufacturers
Primary regulator Jordan Food and Drug Administration, or JFDA
Principal patent framework Jordan Patent Law No. 32 of 1999, as amended
Core regulatory risk Registration, pricing, procurement access, and exclusivity analysis

Jordan’s market is not a simple branded-versus-generic retail market. It has four overlapping channels:

  1. Public hospitals and government procurement.
  2. Private hospitals and clinics.
  3. Community pharmacies.
  4. Export markets supplied by Jordanian manufacturers.

A product can have weak domestic commercial performance but strong export value. Conversely, a high-priced innovator may maintain private-market sales while losing public-tender access to lower-priced generics.

What is the regulatory role of the Jordan Food and Drug Administration?

The JFDA regulates pharmaceutical registration, manufacturing, importation, distribution, quality, pharmacovigilance, inspection, and pricing. Its legal mandate derives principally from the Jordan Food and Drug Administration Law No. 31 of 2008 and the Jordan Drug and Pharmacy Law No. 12 of 2013, together with implementing regulations and technical instructions (Jordan Food and Drug Administration, n.d.-a; Jordan Ministry of Health, 2013).

The JFDA reviews:

  • Marketing authorization applications.
  • Active pharmaceutical ingredient and finished-product quality.
  • Good Manufacturing Practice compliance.
  • Bioequivalence and biowaiver data.
  • Stability data and packaging.
  • Manufacturing-site compliance.
  • Pharmacovigilance systems.
  • Product labeling and Arabic-language requirements.
  • Wholesale, import, and distribution arrangements.

The regulatory pathway depends on product category. Chemical generics generally require pharmaceutical, quality, and bioequivalence documentation. Innovative products require clinical and nonclinical evidence or reliance on approvals from recognized reference jurisdictions. Biological products require more extensive characterization, manufacturing controls, immunogenicity data, and, for biosimilars, comparability evidence.

What are the registration requirements for branded medicines in Jordan?

An originator or innovative medicine normally requires a complete technical dossier, evidence of quality and manufacturing compliance, clinical documentation, and regulatory status in reference markets where applicable.

The principal regulatory issues are:

Reference-country approvals

JFDA review may rely on approvals, assessment reports, or regulatory history from recognized jurisdictions. A product approved by the U.S. Food and Drug Administration, European Medicines Agency, United Kingdom regulators, or other accepted authorities may have a more straightforward regulatory profile than a product with no established reference approval.

Local agent requirements

Foreign companies generally need a Jordanian representative, agent, distributor, or local registration holder to manage submissions, importation, pharmacovigilance, and commercial operations. The contractual structure affects control over regulatory data, change notifications, recalls, and post-approval obligations.

Pricing

Jordan uses pharmaceutical pricing controls. Pricing can depend on reference-country prices, regional prices, manufacturer or CIF prices, exchange rates, and the product’s therapeutic category. The approved price is commercially decisive because pharmacy margins, distributor economics, and public tender bids are constrained.

Post-approval obligations

Marketing authorization holders must manage:

  • Variations.
  • Renewals.
  • Safety updates.
  • Manufacturing-site changes.
  • Label changes.
  • Recalls.
  • Pharmacovigilance reporting.
  • Product shortages and supply continuity.

Registration is therefore a continuing compliance obligation, not a single launch event.

How are generic drugs registered in Jordan?

Generic applicants usually must demonstrate pharmaceutical equivalence and bioequivalence to a reference product or otherwise satisfy JFDA requirements for the relevant dosage form and active ingredient.

A typical generic submission includes:

  • Active ingredient specifications.
  • Finished-product formulation and manufacturing data.
  • GMP evidence.
  • Stability studies.
  • Dissolution testing.
  • Bioequivalence data or an accepted biowaiver.
  • Packaging and labeling.
  • Validation data.
  • Pharmacovigilance commitments.

The strongest generic opportunities are in high-volume chronic therapies, including cardiovascular, diabetes, gastrointestinal, anti-infective, central nervous system, and pain medicines. Competition is intense because multiple Jordanian and foreign manufacturers may target the same molecule after patent or regulatory barriers lapse.

Generic registration risk increases where:

  • The reference product has a narrow therapeutic index.
  • The dosage form is modified-release or complex.
  • The product is inhaled, topical, ophthalmic, or transdermal.
  • The active ingredient is a peptide or biological molecule.
  • The formulation depends on device performance.
  • Bioequivalence requirements are difficult to satisfy.
  • The originator has protected formulation or method-of-use claims.

When does a branded medicine lose exclusivity in Jordan?

Jordan does not use the U.S. Orange Book system as the central mechanism for pharmaceutical patent and regulatory administration. Exclusivity must be analyzed through separate patent, regulatory-data, and market-access channels.

A Jordan launch assessment should identify:

  1. The composition-of-matter patent.
  2. Salt, polymorph, crystal, ester, or solvate patents.
  3. Formulation and dosage-form patents.
  4. Manufacturing-process patents.
  5. Method-of-treatment or dosing-regimen patents.
  6. Regulatory data exclusivity.
  7. Supplementary or extension rights, if applicable.
  8. Compulsory licensing and public-health provisions.
  9. Export-market patent restrictions.

Jordan’s patent regime is based on Patent Law No. 32 of 1999, as amended, and is aligned with the country’s WTO and TRIPS obligations (World Intellectual Property Organization, n.d.; World Trade Organization, 1994).

The Jordan-U.S. Free Trade Agreement includes obligations concerning pharmaceutical test data and undisclosed information. The agreement generally provides a five-year period for protection of undisclosed test data supporting approval of a new pharmaceutical product, subject to the treaty’s conditions and exceptions (United States Trade Representative, 2000).

Data exclusivity does not necessarily create the same commercial position as a granted patent. A product may be protected from reliance on originator clinical data while remaining subject to independent regulatory pathways or patent disputes. Conversely, a patent may expire while data exclusivity or other regulatory barriers remain active.

Does Jordan have Orange Book listings or formal patent linkage?

Jordan does not operate a direct equivalent of the U.S. FDA Orange Book that publicly consolidates approved products, listed patents, therapeutic-equivalence ratings, and Paragraph IV certification procedures.

There is also no Jordanian equivalent of the U.S. Hatch-Waxman Paragraph IV process. A generic applicant does not generally use a Jordan-specific Paragraph IV certification to trigger automatic patent litigation and a statutory stay of approval.

The practical result is that:

  • Patent clearance is primarily the applicant’s responsibility.
  • JFDA marketing authorization and patent enforcement are separate processes.
  • Patent litigation may occur after registration or commercial launch.
  • A patent owner may seek civil remedies, including injunctions and damages, under Jordanian law.
  • Regulatory approval does not itself establish freedom to operate.
  • A generic applicant must conduct a separate Jordan patent search and validity analysis.

Patent linkage risk can still arise commercially. Distributors, hospitals, and tender authorities may avoid products subject to credible infringement claims even where the JFDA has granted registration.

What patent claims protect branded medicines in Jordan?

The most valuable claims depend on the product’s technology and commercial life cycle.

Composition-of-matter patents

These are usually the strongest patents for small-molecule innovators. They protect the active pharmaceutical ingredient itself and can block generic manufacture, importation, and sale before expiration.

Formulation patents

Formulation protection can cover:

  • Extended-release tablets.
  • Enteric coatings.
  • Injectable compositions.
  • Stabilized liquid formulations.
  • Fixed-dose combinations.
  • Liposomal or nanoparticle delivery.
  • Device-cartridge systems.
  • Specific excipient ratios.

Formulation patents are commercially important after a core compound patent expires. Their strength depends on claim scope, validity, enablement, infringement evidence, and whether the generic can design around the claims.

Method-of-use patents

These patents cover specific diseases, patient groups, dosing schedules, biomarker-defined populations, or treatment combinations. Enforcement is more difficult where the generic label omits the protected indication or where pharmacies and physicians substitute products without tracking the patented use.

Manufacturing patents

Process claims can protect difficult-to-manufacture active ingredients, intermediates, crystalline forms, or purification methods. They are most valuable where the process is necessary to produce the commercial product or where alternatives are expensive.

What generic entry risks exist in Jordan?

Generic entry can occur through several scenarios:

Scenario Commercial effect
Core patent expiration Broadest risk to originator sales
Data-exclusivity expiration Enables reliance on protected regulatory data
Formulation patent expiration Opens modified-release or specialty dosage-form competition
Narrow-label generic approval May permit partial market entry
Patent invalidity or non-infringement decision Can accelerate launch
Tender substitution Can shift institutional volume quickly
Unlicensed parallel or informal supply Creates price and compliance pressure
Export-only generic launch May affect regional licensing and supply chains

The most significant risk is usually not the first private-pharmacy launch. It is the loss of institutional volume through government or hospital tenders. Tender awards can reset reference prices and force private-market price reductions.

Originators should assess whether a Jordanian generic manufacturer already has:

  • An approved product.
  • A pending registration.
  • Bioequivalence data.
  • A local manufacturing site.
  • A distribution agreement.
  • Export approvals in neighboring markets.
  • A history of tender participation.

These indicators can reveal launch readiness before commercial sales appear.

Which companies compete in Jordan’s generic market?

Jordan has a substantial domestic manufacturer base. Major locally headquartered or Jordan-based pharmaceutical companies include Hikma Pharmaceuticals, Jordanian Pharmaceutical Manufacturing Company, Dar Al Dawa Development & Investment, United Pharmaceutical Manufacturing, Pharma International, and Arab Pharmaceutical Manufacturing.

Company group Typical strategic position
Hikma Pharmaceuticals Large regional and international generic and injectable platform
Jordanian Pharmaceutical Manufacturing Domestic and export-oriented generic portfolio
Dar Al Dawa Branded generics and regional distribution
United Pharmaceutical Manufacturing Generic manufacturing and local supply
Pharma International Generic and branded-generic products
Arab Pharmaceutical Manufacturing Regional manufacturing and export activity
Multinational innovators Patented, specialty, biologic, and hospital products
Indian and other international generic firms Price competition and contract supply

The competitive landscape is molecule-specific. A branded product may face limited competition in a specialized biologic but intense competition in a mature oral solid dose product.

How does Jordan compare with other Middle East pharmaceutical markets?

Jordan is stronger as a manufacturing and export base than its population alone would suggest. Its advantages include technical manufacturing capability, experienced regulatory personnel, regional market familiarity, and a developed generic sector.

Factor Jordan Gulf markets Egypt
Manufacturing base Strong relative to market size Growing, often import-dependent for finished products Large domestic manufacturing base
Domestic population Small Variable Very large
Generic competition High High but often distributor-led Very high
Tender importance High High High
Export platform Strong Moderate to strong Strong
Price controls Significant Significant Significant
Regulatory complexity Moderate to high High across multiple authorities High
Specialty opportunity Present but limited by reimbursement Stronger in high-income markets Broad but price-sensitive

Jordan can be attractive for companies seeking a regional licensee rather than a stand-alone domestic operation. A local partner can provide regulatory execution, manufacturing, tender access, and export distribution.

What licensing and partnership opportunities exist?

Licensing opportunities are strongest in five areas:

  1. In-licensing of patented or specialty medicines for Jordan and nearby markets.
  2. Out-licensing of Jordanian generics to Africa, Asia, and the Middle East.
  3. Contract manufacturing for finished products and active ingredients.
  4. Technology transfer for injectables, oncology products, and complex dosage forms.
  5. Biosimilar and biological-product partnerships.

A licensing agreement should define:

  • Territory.
  • Registration ownership.
  • Patent prosecution and enforcement.
  • Pharmacovigilance obligations.
  • Supply price and minimum volumes.
  • Tender participation.
  • Manufacturing-site changes.
  • Product recalls.
  • Regulatory data ownership.
  • Export rights.
  • Change-of-control rights.

For branded innovators, a local licensee can reduce fixed operating costs but may create dependence on a single party for regulatory submissions and commercial execution. For Jordanian manufacturers, licensing can expand export revenues but exposes the company to foreign patent litigation, local GMP inspections, and market-specific pricing controls.

What is the biosimilar opportunity in Jordan?

Biosimilars present a longer-term opportunity, but the regulatory and commercial barriers are higher than for ordinary chemical generics.

Key requirements may include:

  • Extensive analytical comparability.
  • Manufacturing-process consistency.
  • Clinical or pharmacokinetic comparability.
  • Immunogenicity assessment.
  • Validated cold-chain controls.
  • Pharmacovigilance.
  • Product-specific interchangeability analysis.

Biosimilar adoption depends on physician confidence, hospital procurement, substitution rules, reimbursement, and the purchasing authority’s willingness to accept lower-cost alternatives. Jordan’s manufacturing base creates an opportunity for biosimilar development and fill-finish partnerships, but biologics require capital, specialized facilities, and stronger quality systems.

Biosimilar applicants must also analyze originator biologic patents in Jordan, including formulation, dosing, manufacturing, device, and treatment-method claims. Biosimilar approval does not eliminate patent infringement risk.

What regulatory challenges affect market access?

The main challenges are:

Pricing and reimbursement pressure

A product may obtain registration but fail commercially if its approved price is too high for public tenders or private reimbursement.

Procurement concentration

Government and hospital purchasing can concentrate demand among a small number of buyers. A single tender decision can materially affect annual sales.

Regulatory timelines

Complex variations, renewals, manufacturing-site changes, and new product registrations can delay launch sequencing.

Import and foreign-exchange exposure

Imported finished products and active ingredients are exposed to logistics costs, currency movements, and supply interruptions.

Quality and GMP compliance

Manufacturers must maintain validated processes, data integrity, stability programs, and inspection readiness. A GMP failure can affect both Jordanian sales and export registrations.

Pharmacovigilance

Local safety reporting and signal management require effective coordination between the marketing authorization holder, local agent, manufacturer, and healthcare providers.

Patent fragmentation

A product may face different patent positions in Jordan, Saudi Arabia, Egypt, the United States, and Europe. Regional launch plans cannot rely on a single global freedom-to-operate analysis.

What are the commercial opportunities for branded and generic companies?

Company type Highest-value opportunity Principal risk
Originator pharmaceutical company Specialty medicines, biologics, oncology, hospital products Price pressure and generic substitution
Jordanian generic manufacturer Export expansion and complex generics Crowded markets and patent exposure
Biosimilar developer Hospital and tender products High development cost and interchangeability limits
Contract manufacturer Technology transfer and regional supply GMP, capacity, and customer concentration
Distributor or local agent Registration and tender representation Dependence on principal and pricing restrictions
Licensing company Regional commercialization Weak exclusivity or limited sales execution

Revenue exposure should be modeled by channel rather than total market size. A useful assessment separates:

  • Private retail revenue.
  • Government tender revenue.
  • Hospital revenue.
  • Export revenue.
  • Chronic versus acute therapies.
  • Patent-protected versus off-patent products.
  • Chemical generics versus biologics.

A mature generic product may have low unit margins but predictable volume. A branded specialty medicine may have high unit value but limited patient access and tender vulnerability.

What is the outlook for Jordan’s pharmaceutical market?

Jordan is likely to remain most attractive as a regional pharmaceutical platform rather than as a high-price standalone market. Generic manufacturers have structural advantages in volume products, local supply, and tender participation. Innovators can compete where products offer differentiated clinical value, address unmet hospital needs, or lack credible generic and biosimilar substitutes.

The most defensible strategy combines:

  • Early patent and data-exclusivity analysis.
  • Local regulatory representation.
  • Price and tender modeling.
  • Selective licensing.
  • Export-oriented manufacturing.
  • Complex-generic or biosimilar capabilities.
  • Strong pharmacovigilance and GMP systems.

Key Takeaways

  • Jordan has a mature generic manufacturing sector and a significant export orientation.
  • JFDA registration, pricing, procurement, and quality compliance determine market access.
  • Jordan has no direct equivalent of the U.S. Orange Book or Paragraph IV system.
  • Patent clearance must be conducted separately from regulatory registration.
  • Composition-of-matter patents provide the strongest protection for small-molecule innovators.
  • Formulation, method-of-use, manufacturing, and biologic patents can extend commercial risk after core patent expiry.
  • Data exclusivity under the Jordan-U.S. Free Trade Agreement is a material regulatory consideration.
  • Government and hospital tenders can accelerate generic substitution and price erosion.
  • Biosimilars offer growth potential but require advanced manufacturing, comparability evidence, and strong pharmacovigilance.
  • Jordan is commercially strongest as a manufacturing, licensing, and regional export base.

FAQs

Does JFDA approval mean that a generic is free to launch in Jordan?

No. JFDA approval addresses regulatory requirements. The applicant must separately assess Jordanian patents, data exclusivity, contractual restrictions, and infringement risk.

Are Jordanian pharmaceutical patents listed in an Orange Book?

No. Jordan does not maintain a direct equivalent of the U.S. Orange Book. Patent status must be assessed through patent-register searches and legal freedom-to-operate analysis.

Can a generic company launch before a Jordanian patent expires?

A launch may be possible if the relevant patent is invalid, not infringed, unenforceable, or does not cover the proposed product or use. The commercial decision requires product-specific legal analysis.

Are biosimilars automatically interchangeable with originator biologics in Jordan?

Automatic interchangeability should not be assumed. Approval, substitution, physician practice, hospital procurement, and product-specific regulatory requirements must be evaluated separately.

Is Jordan a suitable base for pharmaceutical exports?

Yes. Jordan has an established manufacturing sector, experienced pharmaceutical companies, regional distribution links, and a history of export activity. Export profitability still depends on destination-country registration, pricing, GMP compliance, and patent clearance.

References

  1. Jordan Association of Pharmaceutical Manufacturers. (n.d.). Jordan pharmaceutical industry. https://japm.com.jo/

  2. Jordan Food and Drug Administration. (n.d.-a). Jordan Food and Drug Administration. https://www.jfda.jo/

  3. Jordan Food and Drug Administration. (n.d.-b). Drug registration and pharmaceutical regulatory instructions. https://www.jfda.jo/

  4. Jordan Ministry of Health. (2013). Drug and Pharmacy Law No. 12 of 2013.

  5. Jordan Hashemite Kingdom. (1999). Patent Law No. 32 of 1999, as amended.

  6. United States Trade Representative. (2000). United States-Jordan Free Trade Agreement.

  7. World Intellectual Property Organization. (n.d.). WIPO Lex: Jordan intellectual property legislation. https://www.wipo.int/wipolex/

  8. World Trade Organization. (1994). Agreement on Trade-Related Aspects of Intellectual Property Rights. https://www.wto.org/english/docs_e/legal_e/27-trips.pdf

More… ↓

⤷  Start Trial

DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.